• What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model, Bailly C, Gouard S, Guérard F, Chalopin B, Carlier T, Faivre-Chauvet A, et al., IJMS. 24 mai 2019;20(10):2564.

  • Preliminary results of a 68 Ga‐PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision‐making, Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, et al. , Prostate. 17 août 2019;pros.23869

  • Potential for Nuclear Medicine Therapy for Glioblastoma Treatment, Bailly C, Vidal A, Bonnemaire C, Kraeber-Bodéré F, Chérel M, Pallardy A, et al., Front Pharmacol. 10 juill 2019;10:772.

  • Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture, Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, et al., Cancers. 31 août 2019;11(9):1282.

  • Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches, Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, et al., Front Med. 4 juin 2019;6:124.

  • Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT, Foubert F, Gouard S, Saï-Maurel C, Chérel M, Faivre-Chauvet A, Goldenberg DM, Barbet J, Bodet-Milin C, Bailly C, Carlier T, Kraeber-Bodéré F, Touchefeu Y, Frampas E. Oncotarget 2018, 9:27502-27513

  • Synthesis of C-functionalized TE1PA and comparison with its analogues. An example of bioconjugation on 9E7.4 mAb for multiple myeloma 64Cu-PET imaging, Le Bihan T, Navarro AS, Le Bris N, Le Saëc P, Gouard S, Haddad F, Gestin JF, Chérel M, Faivre-Chauvet A, Tripier R, Org Biomol Chem. 2018, 16:4261-4271

  • Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. Bailly C, Gouard S, Lacombe M, Remaud-Le Saëc P, Chalopin B, Bourgeois M, Chouin N, Tripier R, Halime Z, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Chérel M, Bodet-Milin C, Oncotarget 2018, 9:9061-9072

  • Pretargeting in the context of theranostics and companion diagnostics in nuclear oncology. Barbet J. Clin Transl Imaging. (2018) 1-9.

    Translational molecular imaging in exocrine pancreatic cancer. Cornelissen B, Knight JC, Mukherjee S, Evangelista L, Xavier C, Caobelli F, Del Vecchio S, Rbah-Vidal L, Barbet J, de Jong M, van Leeuwen FWB. Eur J Nucl Med Mol Imaging. (2018)45, 2442-2455.

    Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study, Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodere F, Bodet-Milin C , Clin Cancer Res. 2018, 24:5219-5224 IF 10.199 JIF 94.820